ReviewMedical oncology (Northwood, London, England)2022
Niosomes: a novel targeted drug delivery system for cancer.
Review in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 92 citations in OpenAlex.
- Mechanism of action of genistein on breast cancer and differential effects of different age stages.Pharmaceutical biology · 2025Pooled it
- Article
- Niosomal Encapsulation of Anti-cancer Peptides: A Revolutionary Strategy in Cancer Therapy.Current pharmaceutical biotechnology · 2026Review
- Advances in natural product-based nanoparticles for the treatment of acute lung injury.Materials today. Bio · 2025Review
- The apoptotic and anti-metastatic effects of niosome kaempferol in MCF-7 breast cancer cells.Scientific reports · 2025Article
- Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative breast cancer metastasis.Medical oncology (Northwood, London, England) · 2025Article
- "Carnosine-Niosomal Delivery System for Targeted Cancer Therapy".Cell biochemistry and biophysics · 2025Review
- Advancements in Nanocarrier Systems for Nose-to-Brain Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Pharmaceutical and Pharmacological Potential Applications of Bilosomes as Nanocarriers for Drug Delivery.Molecules (Basel, Switzerland) · 2025Review
- Phytochemical insights into flavonoids in cancer: Mechanisms, therapeutic potential, and the case of quercetin.Heliyon · 2025Review
- The simultaneous use of nanovesicles and magnetic nanoparticles for cancer targeting and imaging.Therapeutic delivery · 2025Review
- Bilosomal Co-Encapsulated Tamoxifen and Propranolol for Potentiated Anti-Breast Cancer Efficacy: In Vitro and In Vivo Investigation.Pharmaceutics · 2025Article
- Unraveling the Pivotal Role of Nanovesicle Drug Delivery Systems in Colorectal Cancer: A New Paradigm in Therapeutics.Current pharmaceutical design · 2025Review
- Optimization andAnti-inflammatory & anti-allergy agents in medicinal chemistry · 2025Article
- Exploring the Therapeutic Potential of Vesicular Nanocarrier Systems for Elimination of Skin Cancer.Current medicinal chemistry · 2025Review
- Aripiprazole-loaded niosome/chitosan-gold nanoparticles for breast cancer chemo-photo therapy.BMC biotechnology · 2024Article
- Comparative Study of Lycopene-Loaded Niosomes Prepared by Microfluidic and Thin-Film Hydration Techniques for UVB Protection and Anti-Hyperpigmentation Activity.International journal of molecular sciences · 2024Article
- Nanocarrier-Based Transdermal Drug Delivery Systems for Dermatological Therapy.Pharmaceutics · 2024Review
- Article
- Bee Venom-Loaded Niosomes as Innovative Platforms for Cancer Treatment: Development and Therapeutical Efficacy and Safety Evaluation.Pharmaceuticals (Basel, Switzerland) · 2024Article
Corrections and comments
- Retraction · 2025-03-22Compromised Peer Review · Investigation by Company/Institution · Investigation by Journal/Publisher · Misconduct - Official Investigation(s) and/or Finding(s) · Misconduct by Author · Objections by Author(s) · Paper Mill ·
- Retracted
Authors and funding
9 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, nanotechnology is involved in various fields of science, of which medicine is one of the most obvious. The use of nanoparticles in the process of treating and diagnosing diseases has created a novel way of therapeutic strategies with effective mechanisms of action. Also, due to the remarkable progress of personalized medicine, the effort is to reduce the side effects of treatment paths as much as possible and to provide targeted treatments. Therefore, the targeted delivery of drugs is important in different diseases, especially in patients who receive combined drugs, because the delivery of different drug structures requires different systems so that there is no change in the drug and its effectiveness. Niosomes are polymeric nanoparticles that show favorable characteristics in drug delivery. In addition to biocompatibility and high absorption, these nanoparticles also provide the possibility of reducing the drug dosage and targeting the release of drugs, as well as the delivery of both hydrophilic and lipophilic drugs by Niosome vesicles. Since various factors such as components, preparation, and optimization methods are effective in the size and formation of niosomal structures, in this review, the characteristics related to niosome vesicles were first examined and then the in silico tools for designing, prediction, and optimization were explained. Finally, anticancer drugs delivered by niosomes were compared and discussed to be a suitable model for designing therapeutic strategies. In this research, it has been tried to examine all the aspects required for drug delivery engineering using niosomes and finally, by presenting clinical examples of the use of these nanocarriers in cancer, its clinical characteristics were also expressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.